SynthesisPloS one2025
Predictive value of neutrophil to lymphocyte ratio for clinical outcomes in liver cirrhosis: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal Impairment as an Independent Predictor of Sepsis in Cirrhosis: A Retrospective Cohort Study.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neutrophil-to-lymphocyte ratio (NLR) is a simple yet potent marker that has been established as an independent predictor of mortality in patients with cirrhosis. However, consensus is lacking regarding its prognostic value for predicting mortality risk in these patients. Therefore, we conducted a meta-analysis to clarify its clinical significance.
methodsWe performed a literature search in PubMed, Web of Science, Cochrane Library, and Embase for studies published from database inception until January 1, 2025. Studies focusing on the diagnosis of cirrhosis were included, while those involving children and neonates were excluded. Odds ratio (OR) and its 95% confidence interval (CI) were calculated using the random-effects model. Sensitivity analysis was conducted to assess heterogeneity, subgroup analysis to explore sources of heterogeneity, and Egger's test to evaluate publication bias. All analyses were performed using Review Manager (v5.4.1) and Stata (v15.0).
resultsA total of 18 studies involving 7,714 patients were included. Significant associations were obserced between the NLR and mortality (OR = 1.16, 95% CI: 1.10-1.22; P < 0.00001), infection (OR = 0.67, 95% CI: 0.37-0.96; P < 0.0001), and ascites (OR = 2.03, 95% CI: 1.43-2.88; P < 0.0001). However, no signficant correlation was found between the NLR and hepatic encephalopathy (OR = 1.33, 95% CI: 0.89-2.00; P = 0.16). Subgroup analysis indicated that heterogeneity was partly attributable to variations in NLR cut-off values. Egger's test revealed significant publication bias only for mortality.
conclusionNLR is a well-validated prognostic biomarker for mortality, infection, and ascites in patients with cirrhosis. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD420251031417.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.